Skip to main content
Health & Medicine

Once-Weekly Ribupatide for Weight Loss in Adults in China With Overweight or Obesity: The GEMINI-1 Randomized Clinical Trial.

| Source: JAMA

Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May t

Obesity is a major health problem in China; more pharmacotherapy choices for long-term weight management are needed. To evaluate the efficacy and safety of once-weekly subcutaneous ribupatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist, for weight loss in adults in China with overweight or obesity without diabetes. This multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial was conducted at 55 sites in China. From May to June 2024, adults without diabetes who had a body mass index of 28 or greater or 24 or greater with at least 1 weight-related comorbidity were enrolled, with final follow-up on June 20, 2025. Participants were randomized to receive once-weekly subcutaneous ribupatide (target doses of 2 mg, 4 mg, or 6 mg) or matching placebo for 48 weeks, with dose escalation for up to 20 weeks and concomitant lifestyle intervention. The primary outcome was change in body weight from baseline to week 48, including percent change in body weight and the percentage of participants achieving at least 5% body weight reduction, analyzed under the treatment policy estimand. Among 567 randomized participants (309 [54.5%] female; mean [SD] age was 34.4 [8.4] years, body weight was 93.0 [17.3] kg, and body mass index was 33.3 [4.5]), 514 (90.7%) completed the 48-week treatment period. Least-squares mean percentage changes in body weight at week 48 were -10.7%, -16.4%, and -17.7% with ribupatide 2, 4, and 6 mg, respectively, vs -1.4% with placebo. At week 48, the placebo-adjusted differences in percentage change in body weight were -9.3 (95% CI, -11.4 to -7.3) percentage points with ribupatide 2 mg, -15.0 (95% CI, -17.1 to -12.9) percentage points with ribupatide 4 mg, and -16.3 (95% CI, -18.4 to -14.2) percentage points with ribupatide 6 mg (P < .001 for all). For at least 5% body weight reduction at week 48, the multiply imputed response rates were 68.1% (95% CI, 59.9% to 75.3%) for ribupatide 2 mg (97 of 142), 88.0% (95% CI, 81.3% to 92.6%) for ribupatide 4 mg (124 of 141), 85.7% (95% CI, 78.6% to 90.7%) with ribupatide 6 mg (121 of 141), and 16.0% (95% CI, 10.8% to 23.1%) with placebo (23 of 143). Placebo-adjusted differences for ribupatide 2, 4, and 6 mg were 52.0 (95% CI, 42.2 to 61.9), 72.0 (95% CI, 63.7 to 80.2), and 69.7 (95% CI, 61.1 to 78.3) percentage points, respectively (all P < .001). The most frequent treatment-emergent adverse events with ribupatide were gastrointestinal events, occurring in 47.9%, 58.2%, and 63.1% of participants receiving ribupatide 2 mg, 4 mg, and 6 mg, respectively, compared with 23.1% receiving placebo; most were mild to moderate in severity and few participants (0.7%) permanently discontinued study treatment because of adverse events. Among adults in China with overweight or obesity without diabetes, once-weekly subcutaneous ribupatide resulted in significantly greater weight loss at 48 weeks. Gastrointestinal adverse events were the most frequent tolerability findings. ClinicalTrials.gov Identifier: NCT06396429.

Read the original source →

Related Stories

Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading
Health & Medicine

Elastic interactions of mechanically polarizable cells.

Cells mechanically interact through the deformations they generate in their surrounding extracellular matrix. We present an analytical theory of the elastic interactions between cells that actively adapt their forces in response to local deformations of their environment. Cells are represented as localized contractile force generators, modeled as polarizable point force dipoles, whose adaptive forces are determined self-consistently with those of surrounding cells. Analysis of the associated ela

Continue reading
Health & Medicine

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potent

Continue reading